ClinicalTrials.gg
CompletedNCT07028697Updated Jan 21, 2026

A Study to Evaluate the Efficacy and Safety of Daridorexant in Participants With Insomnia Disorder

A Phase 3 interventional study of Daridorexant and Placebo in Insomnia Disorder, sponsored by Nxera Pharma Korea Co., Ltd.. Completed at 17 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-01-21.

Sponsored by Nxera Pharma Korea Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Dec 2024, registered Jun 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
164
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders — 6 open to participants now, 6 under way, none of them phase 3. daridorexant · Sleep Initiation and Maintenance Disorders.

Enrollment
9th of 16
164 · median 165
Started
2024
with 1 other
Phase 3
5 of 16
none open now
Registered
11th of 16
by date
Lead sponsor
1 of 16
Nxera Pharma Korea Co., Ltd.

Among the 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders, this one is the 9th largest by enrollment, is one of 2 that started in 2024, is one of 5 in phase 3, and was the 11th registered.

Sleep Initiation and Maintenance Disorders

2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 730 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

6 of the 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About daridorexant

daridorexant: first FDA approval 2022 (QUVIVIQ), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 389 Sleep Initiation and Maintenance Disorders studies recruiting now, 152 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 108 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders, or all of them as a file.
02

Study summary

The purpose of this phase 3 study is to evaluate the efficacy and safety of Daridorexant compared to in participants with insomnia disorder.

03

Conditions studied

  • Insomnia Disorder
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed prior to any study-mandated procedure;
  • Male or female aged ≥ 19 years;
  • Insomnia disorder according to criteria;
  • The predominant complaint is dissatisfaction with sleep quantity or quality, associated with one (or more) of the following symptoms:
  • Difficulty initiating sleep.
  • Difficulty maintaining sleep (characterized by frequent awakenings or problems returning to sleep after awakenings).
  • Early-morning awakening with inability to return to sleep.
  • Insomnia Severity Index score ≥ 15;
  • Insufficient sleep quantity as collected subjectively in the sleep diary A. ≥ 30 min to fall asleep, and B. Wake time during sleep ≥ 30 min, and C. Subjective Total Sleep Time (sTST) ≤ 6.5 h

Exclusion criteria

Exclusion Criteria:

  • (BMI) ≥ 40.0 kg/m2
  • Documented medical history and/or comorbidity of sleep-related breathing disorder
  • History of and/or concurrent sleep apnea or suspected sleep apnea
  • Korean--2 (K-MMSE-2) score \< 25 in subjects ≥ 50 years;
  • For female subjects: pregnant, lactating or who do not consent to true abstinence or use an effective method of for required period
  • Initiation of the cognitive behavior therapy (CBT) for treatment of insomnia disorder within 4 weeks prior to the Screening visit (Visit 1) or planned CBT during the study
  • A history of moderate to severe hepatic impairment (eg, Class B or C)
  • Positive urine drug test or presence of alcohol in exhaled breath as detected by breathalyzer test.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
164 participants (actual)

Study arms

  • Experimental
    Daridorexant

    Drug: Daridorexant

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Daridorexant will be taken orally, once daily in the evening as indicated by investigator.

  • DrugPlacebo

    Placebo will be taken orally, once daily in the evening as indicated by investigator.

06

What researchers measure

Primary outcomes

  1. Subjective total sleep time(sTST)

    Change from baseline to week 4 in subjective total sleep time (sTST) measured by eDairy

    Time frame: Week 4

Secondary outcomes

  1. Subjective latency to sleep onset (sLSO)

    Change from baseline to week 4 in subjective latency to sleep onset (sLSO) measured by eDairy

    Time frame: Week 4

  2. Subjective wake after sleep onset (WASO)

    Change from baseline to week 4 in subjective wake after sleep onset (WASO) measured by eDairy

    Time frame: Week 4

07

Study locations

17 sites
  • Inje University Busan Paik Hospital
    Busan, 47392, South Korea
  • Pusan National University Yangsan Hospital
    Busan, 50612, South Korea
  • Soonchunhyang University Cheonan Hospital
    Cheonan, 31151, South Korea
  • Keimyung University Dongsan Medical Center
    Daegu, 42601, South Korea
  • Chungnam National University Hospital
    Daejeon, 35015, South Korea
  • Chonnam National University Hospital
    Gwangju, 61469, South Korea
  • Inje University Ilsan Paik Hospital
    Ilsan, 10380, South Korea
  • Gachon University Gil Medical Center
    Incheon, 21565, South Korea
  • Catholic Kwandong University International St. Mary'S Hospital
    Incheon, 22711, South Korea
  • Seoul National University Bundang Hospital
    Seongnam-si, 13620, South Korea
  • Seoul National University Hospital
    Seoul, 03080, South Korea
  • Severance Hospital
    Seoul, 03722, South Korea
  • Kyung Hee University Hospital At Gangdong
    Seoul, 05278, South Korea
  • Asan Medical Center
    Seoul, 05505, South Korea
  • Ewha Womans University Medical Center
    Seoul, 07804, South Korea
  • The Catholic University of Korea, ST. Vincent's Hospital
    Suwon, 16247, South Korea
  • Wonju Severance Christian Hospital
    Wŏnju, 26426, South Korea
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Sep 2025, 9 months.

Of 29 industry-sponsored phase 3 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's 9 months is below that.

Counting every sponsor, half of 42 studies reached it within 19 months; a quarter within 15 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2025
First posted
Jun 19, 2025
StartActual
Dec 4, 2024
Primary completionActual
Sep 23, 2025
CompletionActual
Oct 21, 2025
Last update
Jan 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07028697
Lead sponsor
Nxera Pharma Korea Co., Ltd.
Responsible party
Sponsor
First posted
Jun 19, 2025
Start date
Dec 4, 2024
Primary completion
Sep 23, 2025
Completion
Oct 21, 2025
Last update
Jan 21, 2026

Study contacts

Clinical Development, Nxera Pharma Korea Co., Ltd.
study director · Nxera Pharma Korea Co., Ltd.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daridorexant

Start the discussion